Fact based stock research
Mezzion Pharma (KOSDAQ:A140410)

KR7140410002

Mezzion Pharma stock research in summary

mezzion.co.kr


Mezzion Pharma shares are more expensive than other comparable stocks. While they show above average growth, they are riskily financed, and are poor value. We recommend evaluating whether the future of the company Mezzion Pharma is really as positive as the high price of the shares suggests. If you come to the conclusion that the future for this company is only average, that could be a reason to sell this share.


Latest Obermatt Ranks


Value Rank 1
Growth Rank 92
Safety Rank 7
Combined Rank 15
Country South Korea
Industry Pharmaceuticals
Index
Size class X-Small

May 7, 2021. Stock data may be delayed. Login to get the most recent research.

Add to Watchlist
Filter Similar Stocks
Similar Top 10

Google: Mezzion Pharma

News

Videos

Wikipedia about Mezzion Pharma

Management

Employee Satisfaction

Customer Satisfaction

Research History: Mezzion Pharma

RESEARCH HISTORY 2018 2019 2020 2021
VALUE
VALUE n/a
n/a
1
1
GROWTH
GROWTH n/a
n/a
64
92
SAFETY
SAFETY n/a
n/a
6
7
COMBINED
COMBINED n/a
n/a
7
15

Last update of Combined Rank: 7-May-2021. Financial reporting date used for calculating ranks: 30-Sep-2020. Stock research history is based on the Obermatt Method. The higher the rank, the better Mezzion Pharma is in the corresponding investment strategy.


Value Metrics in Detail

VALUE METRICS 2018 2019 2020 2021
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S) n/a
n/a
4
2
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E) n/a
n/a
1
1
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book) n/a
n/a
1
1
DIVIDEND YIELD
DIVIDEND YIELD n/a
n/a
1
1
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE n/a
n/a
1
1

Last update of Value Rank: 7-May-2021. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Mezzion Pharma; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2018 2019 2020 2021
REVENUE GROWTH
REVENUE GROWTH n/a
n/a
67
92
PROFIT GROWTH
PROFIT GROWTH n/a
n/a
7
21
STOCK RETURNS
STOCK RETURNS n/a
n/a
100
67
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH n/a
n/a
64
92

Last update of Growth Rank: 30-Sep-2020. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Mezzion Pharma.


Safety Metrics in Detail

SAFETY METRICS 2018 2019 2020 2021
LEVERAGE
LEVERAGE n/a
n/a
51
51
REFINANCING
REFINANCING n/a
n/a
18
24
LIQUIDITY
LIQUIDITY n/a
n/a
1
1
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY n/a
n/a
6
7

Last update of Safety Rank: 30-Apr-2021. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Mezzion Pharma and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Mezzion Pharma from May 7, 2021.


We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.

Get stock news now

Investing made easy